Shukaib Arslan, M.D.
- Acute Leukemias
- Allogeneic Hematopoietic Cell Transplant
- Post-transplant Relapse
- GVHD
- Donor Selection
- Assistant Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation
Location
Duarte Cancer Center
Duarte, CA 91010
Education & Experience
2018, BLS/ACLS
2018, Medical Oncology, American Board of Internal Medicine
2018, Hematology, American Board of Internal Medicine
2015, Professional Critical Care Support, Quality Improvement Boot Camp Training, FCCS
2013, Internal Medicine, American Board of Internal Medicine
2009, Educational Commission for Foreign Medical Graduates
2007, M.B.B.S., King Edward Medical University, Lahore, Pakistan
2018-2020, Fellow, Bone Marrow and Blood Stem Cell Transplant, City of Hope, Duarte, CA
2015-2018, Fellow, Hematology-Oncology, Michigan State University, Ascension St. John Providence Hospital, Southfield, MI
2015-2018, Visiting Fellow Hematology-Oncology, Bone Marrow & Stem Cell Transplant Program, Karmanos Cancer Institute, and subspecialty oncology clinics, Detroit, MI
2017, Visiting Fellow in Stem Cell Transplant and Cellular Therapy, MD Anderson Cancer Center, Houston, TX
2016, Visiting Fellow in Stem Cell Transplant Service, Dana Farber Cancer Institute/Brigham and Women Hospital, Harvard Medical School, Boston, MA
2010-2013, Internal Medicine Residency, Wayne State University,
Detroit Medical Center, Detroit, MI
2020-present, Assistant Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2017-2018, Clinical Instructor, Michigan State University, East Lansing, MI
2014-2015, Assistant Professor, Internal Medicine, University of
Arkansas for Medical Science, Little Rock, AR2014-2015, Hospitalist, Myeloma Institute of Research and Therapy, University of Arkansas for Medical Science, Little Rock, AR
2013-2014, Hospitalist Internal Medicine, Academic Internal Medicine Specialists, Southfield, Ml
2011-2011, Research Assistant, Massey Cancer Center, Virginia Common Wealth University, Richmond, VA
2009, Externship and Research Elective, Department of Preventive Cardiology, University of Pennsylvania, Philadelphia, PA
Awards & Memberships
Awards
2013, Official Photographer Research Day SGH 2013
2006, Official Photographer, KAPS exhibition
2006, First Position in Photography in Fourth Annual KAPS Exhibition
2005, College Photography for College Magazine, KEMCOL
2004, Second Position in Photography, 2nd Annual KAPS exhibition
Memberships
American College of Physicians
American Society of Clinical Oncology
American Society of Hematology
American Society for Blood and Marrow Transplantation
Publications
WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens. Aribi A, Salhotra A, Afkhami M, Munteanu A, Ali H, Aldoss I, Otoukesh S, Al Malki MM, Sandhu KS, Koller P, Arslan S, Stewart F, Artz A, Curtin P, Ball B, O'Hearn J, Spielberger R, Smith E, Budde E, Nakamura R, Stein A, Forman S, Marcucci G, Becker PS, Pullarkat V. Leuk Lymphoma. 2023 Aug 3:1-11. doi: 10.1080/10428194.2023.2241096. Online ahead of print. PMID: 37533373
Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. Yao JM, Otoukesh S, Kim H, Yang D, Mokhtari S, Samara Y, Blackmon A, Arslan S, Agrawal V, Pourhassan H, Amanam I, Ball B, Koller P, Salhotra A, Becker P, Curtin P, Artz A, Aldoss I, Ali H, Stewart F, Smith E, Stein A, Marcucci G, Forman SJ, Nakamura R, Al Malki MM. Transplant Cell Ther. 2023 Aug;29(8):515.e1-515.e7. doi: 10.1016/j.jtct.2023.05.008. Epub 2023 May 12. PMID: 37182736
Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience. Amanam I, Yao J, Puing A, Tsai NC, Samuels D, Ngo D, Ho S, Ali H, Aribi A, Arslan S, Artz A, Htut M, Koller P, Salhotra A, Sandhu K, Nikolaenko L, Pawlowska A, Shouse G, Stein A, Marcucci G, Forman S, Nakamura R, Dadwal S, Al Malki MM. Cancer Med. 2023 May;12(10):11248-11253. doi: 10.1002/cam4.5832. Epub 2023 Apr 20. PMID: 37081733 Free PMC article.
The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study. Ngo D, Chen J, Tinajero J, Aribi A, Arslan S, Marcucci G, Nakamura R, Al Malki MM, Forman SJ, Dadwal S, Ali H. Stem Cell Res Ther. 2023 Apr 18;14(1):95. doi: 10.1186/s13287-023-03326-3. PMID: 37072867 Free PMC article.
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions. Aldoss I, Afkhami M, Yang D, Gu Z, Mokhtari S, Shahani S, Pourhassan H, Agrawal V, Koller P, Arslan S, Tomasian V, Al Malki MM, Artz A, Salhotra A, Ali H, Aribi A, Sandhu KS, Ball B, Otoukesh S, Amanam I, Becker PS, Stewart FM, Curtin P, Smith E, Telatar M, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V. Am J Hematol. 2023 Jun;98(6):848-856. doi: 10.1002/ajh.26908. Epub 2023 Mar 16. PMID: 36880203
Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab. Agrawal V, Pourhassan H, Tsai NC, Ngo D, Koller P, Malki MMA, Salhotra A, Ali H, Aribi A, Sandhu KS, Arslan S, Ball B, Otoukesh S, Amanam I, Artz A, Singh D, Becker PS, Stewart FM, Smith EP, Curtin P, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V, Aldoss I. Transplant Cell Ther. 2023 May;29(5):314-320. doi: 10.1016/j.jtct.2023.01.017. Epub 2023 Jan 19. PMID: 36682470
Hematopoietic stem cell donor vaccination with cytomegalovirus triplex augments frequencies of functional and durable cytomegalovirus-specific T cells in the recipient: A novel strategy to limit antiviral prophylaxis. La Rosa C, Aldoss I, Park Y, Yang D, Zhou Q, Gendzekhadze K, Kaltcheva T, Rida W, Dempsey S, Arslan S, Artz A, Ball B, Nikolaenko L, Pullarkat VA, Nakamura R, Diamond DJ. Am J Hematol. 2023 Apr;98(4):588-597. doi: 10.1002/ajh.26824. Epub 2023 Jan 11.PMID: 36594185
New strategies for mismatched unrelated donor (MMUD) hematopoietic cell transplant (HCT). Arslan S, Al Malki MM. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):74-82. doi:10.1182/hematology.2022000398. PMID: 36485163 Free PMC article.
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML). Ball BJ, Arslan S, Koller P, Ngo D, Afkhami M, Salhotra A, Al-Malki M, Aribi A, Ali H, Sandhu K, Otoukesh S, Amanam I, Pourhassan H, Artz A, Curtin P, Stein A, Nakamura R, Marcucci G, Smith E, Pullarkat V, Aldoss I. Leuk Lymphoma. 2022 Dec;63(13):3232-3236. doi: 10.1080/10428194.2022.2116934. Epub 2022 Sep 10. PMID: 36089918 No abstract available.
Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL. Aldoss I, Yang D, Tomasian V, Mokhtari S, Jackson R, Gu Z, Telatar M, Yew H, Al Malki MM, Salhotra A, Khaled S, Ali H, Aribi A, Sandhu KS, Mei M, Arslan S, Koller P, Artz A, Aoun P, Gu D, Snyder D, Stewart FM, Curtin P, Stein AS, Pillai R, Marcucci G, Forman SJ, Pullarkat V, Nakamura R, Afkhami M. Blood Adv. 2022 Sep 13;6(17):4936-4948. doi: 10.1182/bloodadvances.2022007597. PMID: 35816633 Free PMC article.
- Aldoss I, Dadwal S, Zhang J, Tegtmeier B, Mei M, Arslan S, Al Malki MM, Salhotra A, Ali H, Aribi A, Sandhu K, Khaled S, Snyder D, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Blood Adv. 2019 Dec 10;3(23):4043-4049. doi: 10.1182/bloodadvances.2019000930. PMID: 31816059; PMCID: PMC6963254.
- Aldoss I, Zhang J, Mei M, Al Malki MM, Arslan S, Ngo D, Aribi A, Ali H, Sandhu K, Salhotra A, Koller P, Khaled S, Artz A, Snyder D, Nakamura R, Forman SJ, Stein AS, Marcucci G, Pullarkat V. Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. Am J Hematol. 2020 Jul 6. doi: 10.1002/ajh.25929. Epub ahead of print. PMID: 32628327.
- Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA, Aldoss I, Siebenaller C, Schultz E, Hefazi M, Shallis RM, Yurkiewicz I, Podoltsev N, Patel AA, Curran E, Balasubramanian S, Yang J, Mattison RJ, Burkart M, Dinner S, Liedtke M, Litzow MR, Atallah E. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Adv. 2020 May 26;4(10):2308-2316. doi: 10.1182/bloodadvances.2019001381. PMID: 32453836; PMCID: PMC7252553.
- Arslan S, Nakamura R. Decision Analysis of Transplantation for Patients with Myelodysplasia: "Who Should We Transplant Today?". Curr Hematol Malig Rep. 2020 Aug;15(4):305-315. doi: 10.1007/s11899-020-00573-6. PMID: 32222884.
- Allen J, Wang J, Zolotarskaya OY, Sule A, Mohammad S, Arslan S, Wynne KJ, Yang H, Valerie K. PEAMOtecan, a novel chronotherapeutic polymeric drug for brain cancer. J Control Release. 2020 May 10;321:36-48. doi: 10.1016/j.jconrel.2020.02.003. Epub 2020 Feb 3. PMID: 32027939.
- Badar T, Szabo A, Wadleigh M, Liedtke M, Arslan S, Siebenaller C, Aldoss I, Schultz E, Hefazi M, Litzow MR, Kuo E, Wang A, Curran E, Shallis RM, Podoltsev N, Balasubramanian S, Yang J, Mattison R, Burkart M, Dinner S, Advani A, Atallah E. Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):556-560.e2. doi: 10.1016/j.clml.2020.03.004. Epub 2020 Mar 19. PMID: 32291234.
- Arslan S, Litzow MR, Cummins NW, Rizza SA, Badley AD, Navarro W, Hashmi SK. Risks and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with HIV Infection. Biol Blood Marrow Transplant. 2019 Aug;25(8):e260-e267. doi: 10.1016/j.bbmt.2019.03.021. Epub 2019 Mar 26. PMID: 30926447; PMCID: PMC7144878.
- Arslan S, Zhang J, Dhakal P, Moran J, Naidoo N, Lombardi J, Pullarkat V, Stein AS, Marcucci G, Yaghmour G, Bhatt VR, Fathi AT, Aldoss I. Outcomes of Therapy with Venetoclax Combined with A Hypomethylating Agent in Favorable-Risk Acute Myeloid Leukemia. Am J Hematol. 2020 Nov 23. doi: 10.1002/ajh.26057. Epub ahead of print. PMID: 33227142.
- Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, Atallah E. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer. 2020 Dec 1. doi: 10.1002/cncr.33340. Epub ahead of print. PMID: 33259056.